The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective cohort study of palbociclib in HR+/HER2- metastatic breast cancer in Japan.
 
Takashi Ishikawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; MSD; Pfizer
Research Funding - Chugai Pharma; Lilly; Nihonkayaku
 
Yukari Uemura
Honoraria - Chugai Pharma
Speakers' Bureau - Lilly; Pfizer
 
Hirohito Seki
No Relationships to Disclose
 
Masahiro Kitada
No Relationships to Disclose
 
Takeshi Saito
Speakers' Bureau - Pfizer
 
Kimito Yamada
No Relationships to Disclose
 
Shintaro Takao
No Relationships to Disclose
 
Daisuke Takabatake
No Relationships to Disclose
 
Toru Yokota
No Relationships to Disclose
 
Miyuki Kitahara
No Relationships to Disclose
 
Yuichiro Kikawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
 
Akimitsu Yamada
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Kyowa Kirin International; Lilly Japan; Medicon; MSD; Nipro Corporation; Pfizer; Takeda
 
Uhi Toh
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Pfizer
 
Hideki Nishimura
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; Eisai; Kyowa Kirin Co., Ltd.; Lilly Japan; Pfizer
 
Hiroshi Kaise
No Relationships to Disclose
 
Kazuhiko Yamagami
No Relationships to Disclose
 
Reiki Nishimura
No Relationships to Disclose
 
Naruto Taira
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Kirin Pharmaceuticals; Lilly; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Kirin Pharmaceuticals (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
 
Kazutaka Narui
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); daiichi sankyo (Inst); Lilly Japan (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly Japan; Pfizer
 
Hirofumi Mukai
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Takeda